Rathbones Group PLC Sells 31,326 Shares of Pfizer Inc. (NYSE:PFE)

Rathbones Group PLC cut its stake in Pfizer Inc. (NYSE:PFEFree Report) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 604,222 shares of the biopharmaceutical company’s stock after selling 31,326 shares during the quarter. Rathbones Group PLC’s holdings in Pfizer were worth $17,396,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of PFE. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. GoalVest Advisory LLC raised its stake in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the fourth quarter worth about $36,000. DiNuzzo Private Wealth Inc. acquired a new stake in Pfizer during the fourth quarter worth about $37,000. Finally, Life Planning Partners Inc bought a new position in Pfizer in the 4th quarter valued at about $39,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. Morgan Stanley raised their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $35.86.

Check Out Our Latest Research Report on PFE

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.46 during midday trading on Friday, reaching $28.66. The company had a trading volume of 78,290,055 shares, compared to its average volume of 35,431,976. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The company’s 50 day moving average price is $27.35 and its 200 day moving average price is $27.90. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The stock has a market cap of $162.40 billion, a P/E ratio of -477.59, a P/E/G ratio of 1.11 and a beta of 0.63.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the firm posted $1.23 EPS. Pfizer’s revenue was down 19.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.86%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.